Effect of immune globulin on the prevention of experimental hepatitis C virus infection

Journal of Infectious Diseases

Volumn 173, Issue 4, 1996, Pages 822-828

  Krawczynski, Krzysztof ^a   Alter, Miriam J ^b   Tankersley, Donald L ^b   Beach, Michael ^b   Robertson, Betty H ^b   Lambert, Stephen ^b   Kuo, George ^b   Spelbring, John E ^b   Meeks, Emory ^b   Sinha, Saswati ^b   Carson, Dorrie A ^b  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS ANTIBODY; IMMUNOGLOBULIN;

ANIMAL EXPERIMENT; ARTICLE; CHIMPANZEE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; VIRUS TRANSMISSION;

EID: 19144365016     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.4.822     Document Type: Article

References (28)

1. Alter MJ. The detection, transmission, and outcome of hepatitis C virus infection. Infect Agents Dis 1993;2:155-66.
2. Centers for Disease Control. Public Health Service interagency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR 1991;40(RR-4):1-17.
3. Knodell RG, Conrad ME, Ginsburg AL, Bell CJ, Flannery EP. Efficacy of prophylactic gammaglobulin in preventing non-A, non-B post-transfusion hepatitis. Lancet 1976;1:557-61.
4. Seeff LB, Zimmerman JH, Wright EL, et al. A randomized double-blind controlled trial of the efficacy of immune serum globulin for the preven-tion of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology 1977;72:111-21.
5. Sugg U, Schneider W, Hoffmeister HE, et al. Hepatitis B immune globulin to prevent non-A, non-B post-transfusion hepatitis. Lancet 1985;1:405-6.
6. Sanchez-Quijano A, Pineda JA, Lissen E, et al. Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1988;1:1245-9.
7. Farci P, Alter HJ, Govindarajan S, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-40
8. Farci P, Alter HJ, Wong DC, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci USA 1994;91:7792-6.
9. Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci USA 1994;91:1294-8.
10. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 1992;32:824-8.
11. Louie RE, Galloway CJ, Dumas ML, Wong MF, Mitra G. Inactivation of hepatitis C virus in low pH intravenous immunoglobulin. Biologicals 1994;22:13-9.
12. Spaete RR, Alexander D, Rugroden ME, et al. Characterization of the hepatitis C E2/NS1 gene product expressed in mammalian cells. Virology 1992;188:819-30.
13. Beach MJ, Meeks EL, Mimms LT, et al. Temporal relationships of hepatitis C virus RNA and antibody responses following experimental infection of chimpanzees. J Med Virol 1992;36:226-37.
14. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
15. Enomoto N, Takada A, Hakao T, Date T. There are two major types of hepatitis C virus in Japan. Biochem Biophys Res Commun 1990;170:1021-5.
16. Simmonds P, Holmes EC, Cha TA, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. J Gen Virol 1993;74:2391-9.
17. Krawczynski K, Beach MJ, Bradley DW, et al. Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. Gastroenterology 1992;103:622-9.
18. Bradley DW, Krawczynski K, Ebert JW, et al. Parenterally transmitted non-A, non-B hepatitis: virus-specific antibody response pattern in hepatitis C infected chimpanzees. Gastroenterology 1990;99:1054-60.
19. Udrea MS, Kolberg J, Warner BD, et al. A novel method for the detection of hepatitis B virus in human serum samples without blotting or radioactivity. In: Van Dyke K, Van Dyke R, eds. Luminescence immunoassay and molecular applications. Boca Raton, FL: CRC, 1990:275-91.
20. Lau JYN, Davis GL, Kniffen J, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341: 1501-4.
21. Martell M, Esteban J, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992;66:3225-9.
22. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 1995;15:41-63.
23. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralizing escape mutant viruses. J Virol 1994;68:1494-500.
24. Urushihara A, Sodeyama T, Matsumoto A, Tanaka E. Changes in antibody titers to hepatitis C virus following interferon therapy for chronic infection. J Med Virol 1994;42:348-56.
25. Kawano S, Tanaka M, Fujiyama S, et al. Clinical usefulness of an assay for hepatitis C core in the diagnosis of non-A, non-B hepatitis and monitoring of the response to interferon therapy. J Gastroenterol Hepatol 1994;9:217-22.
26. Chien DY, Choo QL, Ralston R, et al. Persistence of HCV despite antibodies to both putative envelope glycoproteins [letter]. Lancet 1993;342:933.
27. Lesniewski R, OkasinskiG, Carrick R, et al. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol 1995;45:415-22.
28. Ogata N, Ostberg L, Ehrlich PH, Wong DC, Miller RH, Purcell RH. Markedly prolonged incubation period of hepatitis B in a chimpanzee passively immunized with a human monoclonal antibody to the a determinant of hepatitis B surface antigen. Proc Natl Acad Sci USA 1993;90:3014-8.